IL130027A - Rosiglitazone - glyburide synergistic combinations for treatment of diabetes - Google Patents

Rosiglitazone - glyburide synergistic combinations for treatment of diabetes

Info

Publication number
IL130027A
IL130027A IL13002797A IL13002797A IL130027A IL 130027 A IL130027 A IL 130027A IL 13002797 A IL13002797 A IL 13002797A IL 13002797 A IL13002797 A IL 13002797A IL 130027 A IL130027 A IL 130027A
Authority
IL
Israel
Prior art keywords
glyburide
rosiglitazone
diabetes
treatment
synergistic combinations
Prior art date
Application number
IL13002797A
Other languages
English (en)
Other versions
IL130027A0 (en
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL130027A0 publication Critical patent/IL130027A0/xx
Publication of IL130027A publication Critical patent/IL130027A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13002797A 1997-02-19 1997-12-01 Rosiglitazone - glyburide synergistic combinations for treatment of diabetes IL130027A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
PCT/US1997/021996 WO1998036755A1 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergistic combinations for diabetes

Publications (2)

Publication Number Publication Date
IL130027A0 IL130027A0 (en) 2000-02-29
IL130027A true IL130027A (en) 2005-09-25

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13002797A IL130027A (en) 1997-02-19 1997-12-01 Rosiglitazone - glyburide synergistic combinations for treatment of diabetes

Country Status (29)

Country Link
US (2) US5859037A (https=)
EP (1) EP0957923A1 (https=)
JP (1) JP2001512478A (https=)
KR (1) KR20000071179A (https=)
CN (1) CN1244801A (https=)
AR (1) AR011829A1 (https=)
AU (1) AU741215B2 (https=)
BG (1) BG103671A (https=)
BR (1) BR9714505A (https=)
CA (1) CA2272478A1 (https=)
CZ (1) CZ289299A3 (https=)
EA (1) EA199900725A1 (https=)
EE (1) EE9900345A (https=)
GT (1) GT199800037A (https=)
HN (1) HN1997000167A (https=)
HU (1) HUP0001528A3 (https=)
IL (1) IL130027A (https=)
IS (1) IS5058A (https=)
NO (1) NO993982D0 (https=)
NZ (1) NZ336002A (https=)
PA (1) PA8447401A1 (https=)
PE (1) PE74399A1 (https=)
PL (1) PL335166A1 (https=)
SK (1) SK111899A3 (https=)
SV (1) SV1998000010A (https=)
TR (1) TR199902033T2 (https=)
UY (1) UY24893A1 (https=)
WO (1) WO1998036755A1 (https=)
ZA (1) ZA981343B (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
ATE355840T1 (de) * 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
KR20070011651A (ko) * 1997-06-18 2007-01-24 스미스클라인비이참피이엘시이 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
KR100581199B1 (ko) 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
IL143569A0 (en) * 1998-12-24 2002-04-21 Metabasis Therapeutics Inc A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
US6617122B1 (en) * 1999-03-15 2003-09-09 Xenon Genetics, Inc. Process for identifying modulators of ABC1 activity
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
PT1145717E (pt) * 2000-04-13 2004-08-31 Pfizer Prod Inc Efeito sinergistico de gliburide e milrinona
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20100137023A (ko) 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
MXPA06004639A (es) 2003-10-31 2006-06-27 Takeda Pharmaceutical Preparacion solida que comprende sensibilizador de insulina, secretagogo de insulina y ester de acidos grasos de polioxietileno sorbitano.
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Combined drug for treating diabetes
US20090286722A1 (en) * 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
EP1943274A2 (en) * 2005-09-08 2008-07-16 Uutech Limited Treatment of diabetes related obesity
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
ZA200805147B (en) 2005-12-22 2010-05-26 Takeda Pharmaceutical Solid preparation
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
PT2868315T (pt) 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
WO2010065936A1 (en) * 2008-12-04 2010-06-10 Chongxi Yu High penetration compositions and their applications
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
KR101701943B1 (ko) * 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
WO2011146981A1 (en) 2010-05-24 2011-12-01 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions and methods
KR102584819B1 (ko) 2011-01-19 2023-10-05 프랙틸 헬쓰, 인코포레이티드 조직의 치료를 위한 장치 및 방법
EP2782586A4 (en) * 2011-11-23 2015-07-01 Ozstar Therapeutics Pty Ltd ENHANCED SYNERGIC ANTIDIABETIC COMPOSITIONS
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
JP6167115B2 (ja) 2012-02-27 2017-07-19 フラクティル ラボラトリーズ インコーポレイテッド 組織の治療のための熱切除システム、デバイスおよび方法
KR102231179B1 (ko) 2012-04-19 2021-03-22 프랙틸 래브러토리스 인코포레이티드 조직 팽창 디바이스들, 시스템들, 및 방법들
EP2879605A4 (en) 2012-07-30 2016-04-06 Fractyl Lab Inc ELECTRICITY CONTROL SYSTEMS, DEVICES AND METHOD FOR TREATMENT OF TISSUE
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
EP3003461B1 (en) 2013-06-04 2019-05-01 Fractyl Laboratories, Inc. Systems and devices for reducing the luminal surface area of the gastrointestinal tract
WO2015038973A1 (en) 2013-09-12 2015-03-19 Fractyl Laboratories, Inc. Systems, methods and devices for treatment of target tissue
KR102284469B1 (ko) 2013-11-22 2021-08-02 프랙틸 헬쓰, 인코포레이티드 위장관에 치료 제한부를 생성하기 위한 시스템, 장치 및 방법
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
EP3169260B1 (en) * 2014-07-16 2019-09-25 Fractyl Laboratories, Inc. System for treating diabetes and related diseases and disorders
US9757535B2 (en) 2014-07-16 2017-09-12 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
US12403138B2 (en) * 2019-11-22 2025-09-02 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
WO2021146535A1 (en) 2020-01-15 2021-07-22 Fractyl Laboratories, Inc. Automated tissue treatment devices, systems, and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
JP2001512478A (ja) 2001-08-21
US5859037A (en) 1999-01-12
PE74399A1 (es) 1999-08-20
HN1997000167A (es) 1999-02-09
IL130027A0 (en) 2000-02-29
TR199902033T2 (xx) 2000-02-21
IS5058A (is) 1999-05-27
CZ289299A3 (cs) 1999-11-17
PL335166A1 (en) 2000-04-10
US5972973A (en) 1999-10-26
BR9714505A (pt) 2000-03-21
SV1998000010A (es) 1999-02-02
EP0957923A1 (en) 1999-11-24
ZA981343B (en) 1998-11-16
KR20000071179A (ko) 2000-11-25
UY24893A1 (es) 1998-07-10
EE9900345A (et) 2000-02-15
AU741215B2 (en) 2001-11-29
WO1998036755A1 (en) 1998-08-27
NO993982L (no) 1999-08-18
NZ336002A (en) 2002-03-28
AU5590898A (en) 1998-09-09
SK111899A3 (en) 2000-09-12
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
EA199900725A1 (ru) 2000-04-24
HUP0001528A3 (en) 2000-12-28
CA2272478A1 (en) 1998-08-27
BG103671A (en) 2000-04-28
NO993982D0 (no) 1999-08-18
AR011829A1 (es) 2000-09-13
CN1244801A (zh) 2000-02-16
PA8447401A1 (es) 2001-12-14

Similar Documents

Publication Publication Date Title
IL130027A (en) Rosiglitazone - glyburide synergistic combinations for treatment of diabetes
PL337362A1 (en) Treatment of diabetes by means of thiazolydinone and metformin
EP0879279A4 (en) DIABETE TREATMENT
AU7582398A (en) Composition for treating skin conditions
ZA952356B (en) Skin treatment composition
EP1077704A4 (en) COMBINATION THERAPY FOR TREATING DEPRESSION
HUP0100705A3 (en) Combination effective for the treatment of impotence
GB9700899D0 (en) Novel treatment
ZA952121B (en) Skin treatment composition
GB9606076D0 (en) Diabetes treatment
PL337510A1 (en) Treatment of diabetes by means of derivatives of thiazolydinone and sulphonylurea
GB2326116B (en) Treatment of chocolate
EP1007041A4 (en) COMPOSITION FOR TREATING PAIN
GB9703942D0 (en) Grain treatment
IL130831A0 (en) Imino-aza-anthracylinone derivatives for the treatment of amyloidosis
AU7247898A (en) Composition for treating pain
AU4107797A (en) Compounds for the treatment and prevention of diabetes
GB9405046D0 (en) Skin treatment composition
GB9704174D0 (en) Agent for medical treatment
GB0020261D0 (en) Therapeutic treatment
GB2331514B (en) Effluent treatment
GB9618290D0 (en) Treatment of diabetes
GB9721692D0 (en) Novel treatment
GB9609897D0 (en) Treatment of diabetes
GB9815149D0 (en) Treatment of diabetes

Legal Events

Date Code Title Description
MM9K Patent not in force due to non-payment of renewal fees